robbins-llp-logo-white-background1583450-1.png
ALVR INVESTORS: Lead Plaintiff Deadline is Approaching; Contact Robbins LLP for Information About Your Rights
06 mars 2024 18h17 HE | Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
Robbins LLP logo white Background.png
ALVR Shareholders Who Lost Money Should Contact Robbins LLP for Information About the AlloVir, Inc. Class Action
10 févr. 2024 00h49 HE | Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
Robbins LLP logo white Background.png
AlloVir, Inc. (ALVR) Stockholder News: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in AlloVir, Inc. Class Action
29 janv. 2024 19h45 HE | Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
Robbins LLP logo white Background.png
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against AlloVir, Inc. (ALVR)
22 janv. 2024 21h09 HE | Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies